Bain Capital Life Sciences Investors, LLC
An institutional investment manager in Boston, MA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1703031.
- Reported value$1.68bn
- Positions21
Holdings: 21 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Kailera Therapeutics IncKLRA | COMMON STOCK | 482931102 | 498 | 29.6% | 22,583,268 | New+22,583,268 | |
| Heartflow IncHTFL | COM | 42238D107 | 248 | 14.7% | 8,448,158 | Reduced−2,000,000 | |
| Newamsterdam Pharma Company | ORDINARY SHARES | N62509109 | 129 | 7.7% | 3,806,566 | Reduced−3,500,000 | |
| Savara IncSVRA | COM | 805111101 | 108 | 6.4% | 17,600,621 | Unchanged | |
| Alkermes plc | SHS | G01767105 | 102 | 6.0% | 1,937,938 | Added+1,327,938 | |
| Solid Biosciences IncSLDB | COM NEW | 83422E204 | 98.0 | 5.8% | 9,808,819 | Unchanged | |
| Pharvaris N V | COM | N69605108 | 92.5 | 5.5% | 2,675,509 | Unchanged | |
| Olema Pharmaceuticals IncOLMA | COM | 68062P106 | 88.6 | 5.3% | 7,085,249 | Reduced−387,989 | |
| Hemab Therapeutics Holdings IncCOAG | COM SHS | 423494103 | 60.6 | 3.6% | 1,650,000 | New+1,650,000 | |
| Cabaletta Bio IncCABA | COM | 12674W109 | 53.6 | 3.2% | 17,241,445 | Added+7,564,320 | |
| X4 Pharmaceuticals IncXFOR | COM NEW | 98420X202 | 37.2 | 2.2% | 7,967,454 | Unchanged | |
| Dianthus Therapeutics IncDNTH | COM | 252828108 | 35.3 | 2.1% | 362,470 | Unchanged | |
| C4 Therapeutics IncCCCC | COM STK | 12529R107 | 33.5 | 2.0% | 7,171,910 | Unchanged | |
| Kyverna Therapeutics IncKYTX | COM | 501976104 | 25.7 | 1.5% | 2,885,000 | Reduced−225,000 | |
| Annexon IncANNX | COM | 03589W102 | 25.3 | 1.5% | 4,437,731 | Reduced−774,943 | |
| Rapid Micro Biosystems IncRPID | CLASS A COM | 75340L104 | 14.6 | 0.9% | 8,434,560 | Unchanged | |
| Disc Medicine IncIRON | COM | 254604101 | 10.3 | 0.6% | 141,234 | Unchanged | |
| Atea Pharmaceuticals IncAVIR | COM | 04683R106 | 9.7 | 0.6% | 2,075,639 | Reduced−284,999 | |
| Xilio Therapeutics IncXLO | COM | 98422T209 | 6.4 | 0.4% | 664,021 | Unchanged | |
| Upstream Bio IncUPB | COM | 91678A107 | 4.2 | 0.2% | 600,949 | Reduced−266,262 | |
| Newamsterdam Pharma Company | *W EXP 99/99/999 | N62509117 | 2.1 | 0.1% | 99,999 | Unchanged |
Sold out: 1 position
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Centessa Pharmaceuticals | SPONSORED ADS | 152309100 | 0.0 | 0.0% | 0 | Sold out−635,000 |
Source: SEC EDGAR, Form 13F-HR, accession 0001193125-26-350470 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.